Please provide your email address to receive an email when new articles are posted on . Madrigal Pharmaceutical’s Rezdiffra received accelerated FDA approval for the treatment of patients with ...
CLEVELAND — Metabolic dysfunction-associated steatohepatitis, or "MASH," is caused when fat builds up in and around the liver. It's often associated with high blood pressure, Type 2 diabetes, and ...
Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved ...
CONSHOHOCKEN, Pa., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...
Patients in the Phase 3 MAESTRO-NAFLD-1 trial achieved a statistically significant mean reduction of 6.7 kPa in liver stiffness, the largest reported in compensated MASH cirrhosis populations. 51% of ...
With sales of $103 million in the fourth quarter and $180 million in its first nine months on the market, Madrigal Pharmaceuticals’ metabolic dysfunction-associated steatohepatitis (MASH) treatment ...
With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. According to ...
Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results